BioMedNewsBreaks

ThursdayNov 16, 2023 12:04 pm

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Releases Q3 2023 Financial Report, Corporate Update

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, is reporting on its financial results as well as providing a comprehensive business update for the third quarter ended Sept. 30, 2023. Highlights of the report include the successful conclusion of a crucial Type-B meeting with the U.S. Food and Drug Administration designed to gather vital guidance for the NDA submission of PAX-101; the completion of the final PAX-101 phase 3 trials for human African trypanosomiasis (HAT); the strategic acquisition of suramin research assets from Rediscovery Life Sciences (RLS); and the successful completion of a commercial-scale development plan for…

Continue Reading

WednesdayNov 15, 2023 3:47 pm

BioMedNewsBreaks – NextPlat Corp.’s (NASDAQ: NXPL) Strong Growth Featured in Proactive Podcast

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, was featured in an interview with Proactive, where its CEO Charlie Fernandez joined host Steve Darling to provide an update on the company’s latest financial results. NextPlat has made impressive strides in consolidating its global e-commerce and Progressive Care health care operations, leading to significant growth. During the interview, Fernandez highlighted the company’s strong financial performance in the third quarter, reporting consolidated revenues of $15.3 million. This represents a remarkable >481% increase compared to the third quarter of the previous year. In addition, the company’s gross margins saw substantial improvement, reaching 30%…

Continue Reading

WednesdayNov 15, 2023 1:24 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Filing of Supplement to Management Information Circular

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has filed a supplement related to certain restrictions on resale that will apply to the Celly Nu shares that will be distributed to the FSD Pharma securityholders. The company filed the supplement, dated Nov. 15, 2023, as an addition to the Management Information Circular that was filed last month; the company noted that capitalized terms not defined in this news release have the meanings assigned in the circular. The supplement was filed in connection with the company’s upcoming…

Continue Reading

WednesdayNov 15, 2023 1:05 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Q3 2023 Financial Results, Update on Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is reporting on its financial results for third quarter, the period ended Sept. 30, 2023; the company also noted upcoming milestones. Notable financial numbers from the report include net loss for Q3 totaled approximately $4.5 million compared to an estimated $3.4 million for the comparable period in 2022; R&D expenses came in at $3.4 million for the third quarter compared to approximately $2.2 million for the comparable period in 2022; and general and administrative…

Continue Reading

WednesdayNov 15, 2023 12:26 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q3 2023 Financial Report, Operational Update

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, allowing for the creation of rich data for artificial intelligence (“AI”), is reporting its financial and operational results for the third quarter ended Sept. 30, 2023. Highlights of the report include the publication of a foundational study demonstrating the ability of HeartBeam’s VECG technology platform to detect the presence of coronary artery occlusions in the “Journal of American College Cardiology”; several new management and board of director appointments; and significant progress made toward key milestones…

Continue Reading

TuesdayNov 14, 2023 2:58 pm

BioMedNewsBreaks – SOHM Inc. (SHMN) Unveils New Suite of SOHM Nutrients’ Brand Chewables

SOHM (OTC: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, has announced a new suite of products in the vitamin gummies space. Provided by the SOHM OTC Self-Care business unit, the new line includes 13 new SOHM Nutrients’ Brand Chewables. The new suite of chewable products offers an array of key benefits, including bone and skin health, an immune boost, mineral replenishment and sleep aid. The pocket-friendly products come in four flavors — mango, strawberry, pineapple and toffee — and are single serving, individually wrapped. The vegan chewables contain key ingredients,…

Continue Reading

TuesdayNov 14, 2023 2:45 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Q1 Fiscal 2024 Financial Results, Provides Business Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today released financial results for the first quarter of the fiscal year 2024, which ended Sept. 30, 2023. “We are pleased with the continued advancements across our pharmaceutical programs and commercial operations. We are particularly excited with the recent candidate selection and official launch of our INM-901 preclinical program targeting the treatment of Alzheimer’s disease, representing a unique and innovative treatment approach compared to current options available to patients. Our commercial subsidiary, BayMedica, continues to make steady progress as a…

Continue Reading

TuesdayNov 14, 2023 12:24 pm

BioMedNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Featured in Bell2Bell Podcast

Longeveron (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, was featured in the latest episode of the Bell2Bell Podcast, a part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels. Longeveron’s CEO Wa’el Hashad joined the program to introduce the company and its business model. “Longeveron is a cell therapy-based biotech company. It was established in 2014 as a spin-off from a technology that was developed at the University of Miami School of Medicine by a renowned scientist and cardiologist, Dr. Josh Hare,” Hashad said. “Josh has been…

Continue Reading

MondayNov 13, 2023 10:08 am

BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Study Survival Data Reported at AHA’s 2023 Scientific Sessions

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-Related Frailty, is reporting on data from a long-term study. According to the announcement, extended long-term, follow-up data from Longeveron’s  ELPIS I trial of Lomecel-B(TM) for patients with hypoplastic left heart syndrome (“HLHS”) is being presented as a poster at the annual Scientific Sessions of the American Heart Association (AHA); those sessions are being held this week, Nov. ­11­-13, 2023, in Philadelphia. The poster for the sessions is titled “Long-Term Transplant-Free Survival Is Improved in…

Continue Reading

FridayNov 10, 2023 1:49 pm

BioMedNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Announces 2023 Results, Provides Corporate Update

Longeveron (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced its results for the quarter ended Sept. 30, 2023, and provided a corporate update. “During our third quarter and in recent weeks, we continued to advance our Lomecel-B(TM) clinical programs, highlighted by positive top-line results from our CLEAR MIND clinical trial of Lomecel-B(TM) in the treatment of mild Alzheimer’s disease and acceptance of ELPIS I long-term survival data for presentation at the American Heart Association annual meeting. We also took steps to strengthen our balance sheet, securing $4 million of gross proceeds from…

Continue Reading